Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$37.66-0.6%$37.41$31.72▼$45.93$77.95B0.584.47 million shs3.72 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK-2.55%-2.14%+0.62%+11.83%-10.83%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSKGSK3.1657 of 5 stars2.35.02.50.03.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 2.60Moderate Buy$43.2515.09% UpsideCurrent Analyst Ratings BreakdownLatest GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/12/2025GSKGSKMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$31.38B2.48$5.95 per share6.32$8.07 per share4.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$3.29B$1.5923.648.081.128.13%48.59%11.11%4/30/2025 (Estimated)Latest GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025N/AGSKGSK$1.06N/AN/AN/A$7.52 billionN/A2/5/2025Q4 2024GSKGSK$0.44$0.59+$0.15$0.26$7.75 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.574.18%-17.33%98.74%N/ALatest GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/5/2025GSKGSKquarterly$0.39324.2%2/21/20252/21/20254/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK1.120.780.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK90,1002.07 billion1.87 billionOptionableGSK HeadlinesRecent News About These CompaniesGSK: Under Threat From 'Double Whammy' Of Vaccine Skepticism And Pharma TariffsApril 2 at 6:00 PM | seekingalpha.comGSK LAWSUIT ALERT: Levi & Korsinsky Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming DeadlineApril 2 at 6:00 PM | accessnewswire.comGSK Deadline: GSK Investors Have Opportunity to Lead GSK plc Securities Fraud LawsuitApril 2 at 5:25 PM | prnewswire.comGSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSKApril 2 at 4:30 PM | accessnewswire.comGSK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GSK plc Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 2 at 4:00 PM | globenewswire.comShareholders that lost money on GSK plc (GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreApril 2 at 2:45 PM | accessnewswire.comGSK DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GSK plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – GSKApril 2 at 2:25 PM | globenewswire.comWill Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?April 2 at 1:15 PM | zacks.comGSK plc Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GSKApril 2 at 12:00 PM | accessnewswire.comGSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitApril 2 at 12:00 PM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSKApril 2 at 10:00 AM | accessnewswire.comShareholders that lost money on GSK plc (GSK) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreApril 2 at 9:30 AM | accessnewswire.comGSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law FirmApril 2 at 9:07 AM | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit - GSKApril 2 at 7:25 AM | accessnewswire.comGSK plc (NYSE:GSK) Shares Sold by Tweedy Browne Co LLCApril 2 at 6:46 AM | marketbeat.comLPL Financial LLC Buys 18,519 Shares of GSK plc (NYSE:GSK)April 2 at 3:49 AM | marketbeat.comGSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitApril 1 at 4:22 PM | prnewswire.comLevi & Korsinsky Notifies Shareholders of GSK plc(GSK) of a Class Action Lawsuit and an Upcoming DeadlineApril 1 at 3:00 PM | accessnewswire.comGSK plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – GSKApril 1 at 1:32 PM | globenewswire.comWhich Is a Better Investment, Corcept Therapeutics Incorporated or GSK plc Stock?April 1 at 1:09 PM | aaii.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc(GSK) ShareholdersApril 1 at 12:30 PM | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSK Company DescriptionsGSK NYSE:GSK$37.66 -0.21 (-0.55%) Closing price 03:58 PM EasternExtended Trading$37.52 -0.13 (-0.36%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Targets Signal More Growth in CrowdStrike Stock NextEra Energy Stock Sees Spike in Bullish Call Activity 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Why Howmet Could Be the Sleeper Aerospace Name of 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
